|
Characteristic
|
Total (cases)
|
Deaths [cases (%)]
|
Unadjusted HR (95 % CI)
|
P value
|
|---|
|
Total
|
672
|
458
| | |
|
Gender
| | | | |
|
Male
|
546
|
371 (67.9)
|
Reference
|
0.700
|
|
Female
|
126
|
87 (69.0)
|
1.05 (0.83, 1.32)
| |
|
Age (years)
| | | | |
|
<46
|
316
|
213 (67.4)
|
Reference
|
0.124
|
|
≥46
|
356
|
245 (68.8)
|
1.16 (0.96, 1.39)
| |
|
T stage*
| | | | |
|
T1-2
|
273
|
184 (67.4)
|
Reference
|
0.975
|
|
T3-4
|
399
|
274 (68.7)
|
1.00 (0.83, 1.20)
| |
|
N stage*
| | | | |
|
N0-1
|
273
|
172 (63.0)
|
Reference
|
<0.001
|
|
N2-3
|
399
|
286 (71.7)
|
1.42 (1.18, 1.72)
| |
|
Metastasis at presentation
| | | | |
|
Absent
|
375
|
261 (69.6)
|
Reference
|
0.825
|
|
Present
|
297
|
197 (66.3)
|
0.98 (0.81, 1.18)
| |
|
Number of metastatic lesions
| | | | |
|
1
|
105
|
51 (48.6)
|
Reference
|
<0.001
|
|
≥2
|
567
|
407 (71.8)
|
2.06 (1.54, 2.77)
| |
|
Bone metastasis
| | | | |
|
Absent
|
280
|
196 (70.0)
|
Reference
|
0.862
|
|
Present
|
392
|
262 (66.8)
|
1.02 (0.85, 1.22)
| |
|
Liver metastasis
| | | | |
|
Absent
|
443
|
283 (63.9)
|
Reference
|
<0.001
|
|
Present
|
229
|
175 (76.4)
|
1.62 (1.34, 1,95)
| |
|
Lung metastasis
| | | | |
|
Absent
|
462
|
309 (66.9)
|
Reference
|
0.847
|
|
Present
|
210
|
149 (71.0)
|
0.98 (0.81, 1.19)
| |
|
Extraregional lymph node metastasis
| | | | |
|
Absent
|
497
|
328 (66.0)
|
Reference
|
0.060
|
|
Present
|
175
|
130 (74.3)
|
1.22 (0.99, 1.49)
| |
|
EBV VCA/IgA
| | | | |
|
<1:80
|
80
|
48 (60.0)
|
Reference
|
0.413
|
|
1:80–1:320
|
395
|
270 (68.4)
|
1.15 (0.84, 1.56)
| |
|
≥1:640
|
197
|
140 (71.1)
|
1.17 (0.85, 1.63)
| |
|
EBV EA/IgA
| | | | |
|
<1:10
|
128
|
84 (65.6)
|
Reference
|
0.385
|
|
1:10–1:20
|
216
|
149 (69.0)
|
0.97 (0.74, 1.27)
| |
|
≥1:40
|
328
|
225 (68.6)
|
0.91 (0.71, 1.16)
| |
|
Lymphocyte count (× 109/L)
| | | | |
|
<1.390
|
340
|
250 (73.5)
|
Reference
|
0.002
|
|
≥1.390
|
332
|
208 (62.7)
|
0.75 (0.63, 0.90)
| |
|
Monocyte count (× 109/L)
| | | | |
|
<0.665
|
428
|
263 (61.4)
|
Reference
|
<0.001
|
|
≥0.665
|
244
|
195 (80.0)
|
2.17 (1.80,2.62)
| |
|
LMR
| | | | |
|
<2.475
|
335
|
269 (80.3)
|
Reference
|
<0.001
|
|
≥2.475
|
337
|
189 (56.1)
|
0.45 (0.37, 0.54)
| |
- HR, hazard ratio; CI, confidence interval; EBV, Epstein-Barr virus; VCA/IgA, immunoglobulin A against viral capsid antigen; EA/IgA, immunoglobulin A against early antigen; LMR, lymphocyte-to-monocyte ratio. *The American Joint Committee on Cancer (AJCC) 2002 system was used for staging at the diagnosis of NPC
